Meeting
2023 ASCO Genitourinary Cancers Symposium
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for 177Lu-PSMA therapy in advanced prostate cancer.
Authors
Alin Chirindel
University Hospital Basel, Basel, Switzerland
Alin Chirindel , Mark Kidd , Cyrill A. Rentsch , Frank Stenner , Arnoud J. Templeton , Egbert Nitzsche , Damian Wild , Guillaume Nicolas , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 183)
DOI
10.1200/JCO.2023.41.6_suppl.183
Abstract #
183
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
First Author: Ekamjit Singh Deol
Poster
2023 ASCO Annual Meeting
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM).
First Author: Nishita Tripathi
Poster
2022 ASCO Genitourinary Cancers Symposium
A microRNA-based classifier for identification of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
First Author: Sharanjot Saini